Trulicity Lawsuit [year] | Stomach Paralysis and Vision Loss Claims

Trulicity is one of several GLP-1 receptor agonist diabetes medications prescribed to treat type 2 diabetes and, in some cases, discussed alongside drugs marketed as a weight loss drug.

It is administered as a once-weekly injection and is frequently compared to other GLP-1 medications such as Ozempic and Mounjaro, which serve similar therapeutic purposes but differ in dosing and reported side effect profiles.

In recent litigation, plaintiffs allege that Trulicity injuries extend beyond routine side effects and raise serious concerns about long-term health risks.

Lawsuits describe patients suffering from persistent gastrointestinal symptoms, including severe nausea, vomiting, and impaired stomach emptying.

Additional claims involve vision-related injuries that patients say developed after sustained use of GLP-1 drugs.

Emerging data has led many patients and healthcare providers to compare Trulicity with Ozempic and Mounjaro when evaluating safety risks.

Federal regulators have also taken notice of these reported complications.

These issues now form the foundation of coordinated legal actions involving Trulicity and other GLP-1 medications:

• Trulicity, Ozempic, and Mounjaro are all GLP-1 receptor agonists approved to treat type 2 diabetes.
• Studies and adverse event reports have associated GLP-1 medications with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss.
• The FDA has added warnings to GLP-1 drug labels, including Trulicity and Ozempic, regarding gastrointestinal complications.
• Patients increasingly compare side effects across GLP-1 drugs, particularly gastrointestinal issues and reported cases of vision impairment.

Why Trulicity Is Named in the GLP-1 Litigation

Trulicity is included because it belongs to the same GLP-1 drug class as other medications under scrutiny, and lawsuits claim that class-wide effects on gut motility may be relevant to the injuries alleged.

Plaintiffs generally contend that slowing gastric emptying can, in some cases, progress from temporary digestive disruption to more serious problems involving the stomach muscles, including allegations described as stomach paralysis and complications like bowel obstruction.

In other words, the claim is not that everyone will be harmed, but that a subset of patients who suffered severe and persistent symptoms may have experienced an abnormal or prolonged effect on digestion and intestinal movement.

These filings remain allegation-based, and the litigation process is designed to test what the evidence shows about risk, labeling, and causation for individual patients who report severe gastrointestinal disease and related complications such as severe abdominal pain and ongoing digestive dysfunction.

Trulicity Lawsuit Settlement Amounts: Projections and Estimates

Lawyers estimating potential Trulicity lawsuit settlement amounts often place projected case values in a broad range of about $50,000 to over $700,000, depending on the severity of the alleged injury and the strength of the supporting medical evidence.

No Trulicity settlement program has been announced, and there is no established “average” payout at this stage, so any figures discussed publicly should be treated as projections, not guaranteed outcomes.

Because Trulicity falls within the same broader GLP-1 litigation category as Ozempic and similar drugs, projected values are typically discussed in tiers that rise with documented severity, treatment intensity, and long-term impairment.

Higher-end projections are generally associated with cases involving confirmed, severe diagnoses, repeated emergency care, hospitalization, surgical intervention, or lasting disability, while lower-end projections tend to involve less intensive treatment or shorter symptom duration.

Even within the same projection range, case value can vary widely based on medical timelines, alternative causes, and the completeness of records linking Trulicity use to the alleged complication.

Other Drugs and Manufacturers Named in the GLP-1 Lawsuits

Over the last several years, GLP-1 prescriptions have surged because these drugs are widely discussed not only for diabetes control but also for weight loss and long-term chronic weight management, including use patterns that expanded public awareness and demand.

As more patients started these therapies, more people also reported severe gastrointestinal symptoms, prompting closer scrutiny from clinicians, regulators, and plaintiffs’ attorneys.

Many complaints describe symptoms that go beyond expected transient nausea—such as recurring vomiting, delayed gastric emptying, and episodes of severe stomach pain—which is part of why this litigation is unfolding as a coordinated proceeding.

Some complaints also include eye-related allegations, including non arteritic anterior ischemic optic neuropathy claims and, in some reports, references to arteritic anterior ischemic optic events, which involve compromised blood flow to structures in the eye.

Other GLP-1 drugs commonly named in the broader lawsuits include:

• Ozempic (semaglutide)
• Wegovy (semaglutide)
• Rybelsus (oral semaglutide)
• Mounjaro (tirzepatide)
• Zepbound (tirzepatide)

GLP-1 drugs were originally developed to treat diabetes by improving blood sugar control, but their use has expanded rapidly alongside growing interest in weight loss medications.

As prescriptions increased, patients and clinicians began reporting a wider range of adverse effects beyond those described in early clinical trials.

Medical literature and post-marketing data have raised concerns about gastrointestinal complications, particularly when these drugs are used long term.

Some patients report ongoing symptoms such as persistent nausea, vomiting, abdominal pain, and delayed gastric emptying that do not resolve after discontinuation.

More recent reports and studies have also explored a possible association between GLP-1 drugs and vision-related injuries, including conditions that may lead to partial or permanent vision loss.

These reports form the basis of allegations that some users experienced debilitating symptoms after taking medications intended to treat diabetes and promote weight loss.

Severe Gastrointestinal Issues Alleged in GLP-1 Lawsuits

A central issue in GLP-1 litigation is that the same mechanism that helps regulate appetite and glucose levels may also interfere with normal gastrointestinal motility.

Because these drugs can slow gastric emptying, some plaintiffs describe a progression of gastrointestinal risks that began with nausea and bloating and later developed into more serious, persistent complications such as severe abdominal pain and repeated vomiting.

In these lawsuits, plaintiffs argue that their symptoms became disabling and were later diagnosed as severe gastroparesis, sometimes described in patient records and testimony as “stomach paralysis,” or other intestinal motility disorders such as ileus.

These allegations frequently rely on medical timelines showing symptom onset after the use of a prescription medication and diagnostic testing intended to rule out alternative causes.

Regulators have also acknowledged reports of serious gastrointestinal complications within this drug class.

Certain GLP-1 drug labels have been updated to include postmarketing reports of ileus, reflecting concerns raised through adverse event reporting and ongoing safety monitoring.

Plaintiffs in the MDL and related filings argue that these risks were not adequately communicated to patients or prescribing providers before widespread use increased.

Gastrointestinal complications alleged in GLP-1 litigation include:

• Gastroparesis and delayed gastric emptying, including cases described as severe gastroparesis
• Persistent nausea and vomiting with prolonged delayed stomach emptying
• Severe abdominal pain and stomach cramping associated with impaired digestive motility
• Ileus, sometimes described as intestinal “shutdown” or loss of bowel function
• Symptoms consistent with bowel obstruction requiring emergency care and diagnostic imaging
• Complications tied to prolonged vomiting, including dehydration, malnutrition, and repeat hospital visits
• Episodes of acute gastrointestinal distress requiring specialist evaluation and follow-up treatment

These allegations can overlap with other health conditions, including high blood pressure and other comorbidities that may complicate diagnosis and causation analysis.

The litigation typically focuses on whether a patient’s medical history, symptom progression, and clinical testing support a causal link between the drug and the alleged injury.

Some complaints also reference other serious complications, including deep vein thrombosis, though gastrointestinal motility conditions remain the primary focus in many GLP-1 filings.

Vision Loss Potentially Linked to GLP-1 Usage

Separately, some claimants allege a connection between GLP-1 use and ischemic optic neuropathy NAION (non-arteritic anterior ischemic optic neuropathy).

NAION involves reduced blood supply to the optic nerve, and it often presents as sudden, painless vision loss or a “shadow/curtain” effect in one eye, sometimes noticed upon waking.

Because the injury is tied to ischemia (insufficient blood flow), it can be permanent; recovery is unpredictable, and there is no guaranteed way to reverse it once optic nerve tissue is damaged.

These claims have become large enough that the United States Judicial Panel on Multidistrict Litigation centralized federal NAION cases into a separate MDL (MDL No. 3163) in the Eastern District of Pennsylvania, distinct from the GI-focused GLP-1 MDL.

The JPML’s transfer order reflects the procedural conclusion that the cases share common factual questions about the products and their alleged capacity to cause non arteritic anterior ischemic optic neuropathy (NAION).

You may qualify for a Trulicity lawsuit if you used Trulicity (dulaglutide), a GLP-1 medication made by Eli Lilly, and later experienced severe symptoms that required medical attention or medical intervention.

Many claims focus on digestive injuries tied to slow gastric emptying, including persistent vomiting, inability to tolerate meals, and findings of undigested food in the stomach on imaging or endoscopy.

Some patients report chronic nausea and escalating severe pain that does not improve with standard treatment, leading to repeat ER visits or specialist referrals.

Other filings allege motility disorders that can present like an intestinal blockage, including ileus-type symptoms and other severe complications requiring hospitalization.

Separate from GI allegations, some people seek legal review after sudden vision loss or other vision loss symptoms later diagnosed as anterior ischemic optic neuropathy.

Qualification is usually fact-specific and depends on the timeline of use, symptom onset, testing results, and individual risk factors, including other health conditions and medications.

Evidence Commonly Reviewed in GLP-1 Lawsuits

Evidence matters because these cases turn on medical timelines, objective findings, and documented treatment, not assumptions about what “should” have happened.

A strong record helps show when symptoms began, what tests confirmed, what providers concluded, and what care was needed to address serious health problems.

It also helps counsel and experts assess alternative explanations and known risk factors that could affect causation.

In coordinated proceedings overseen through a judicial panel process and managed by the MDL court (including matters before District Judge Karen Marston), consistent documentation is often the difference between a claim that can be evaluated and one that cannot.

Common evidence includes:

• Pharmacy and prescribing records showing Trulicity start/stop dates, dose changes, and refill history (plus other GLP-1 prescription drugs, if any)
• Primary care notes and specialist records (GI, ophthalmology, neurology) documenting severe symptoms, chronic nausea, severe pain, or sudden vision loss
• Emergency department and hospitalization records, including discharge summaries and admission notes
• Diagnostic testing: endoscopy reports noting undigested food, gastric emptying studies (for slow gastric emptying), CT scans, X-rays, and labs
• Diagnosis documentation for GI conditions such as gastroparesis, ileus, or symptoms consistent with intestinal blockage
• Eye exam records and imaging supporting anterior ischemic optic neuropathy or related findings
• Treatment history showing medical intervention (IV fluids, NG tube, surgery, medication changes) and follow-up plans
• Work and income records showing time missed from work and any lost wages

Damages in Trulicity Lawsuit Claims

“Damages” refers to the losses a person claims resulted from an injury, and it is one of the most fact-driven parts of a case.

Lawyers typically assess damages by reviewing medical records, billing, prognosis, and how the condition changed a person’s daily function over time.

In GI cases, damages often hinge on the severity and duration of symptoms, whether the person needed hospitalization, and whether the condition caused life altering complications or long-term dietary restrictions.

In vision-related cases, damages can depend on the extent of impairment, whether it involved sudden vision loss, and what limitations persist after treatment.

Attorneys also consider whether a person’s history includes other relevant exposures or comorbidities, and they may consult medical and financial experts to quantify both past costs and future needs.

Damages commonly sought include:

• Past and future medical costs, including testing, hospital care, and follow-up medical attention
• Out-of-pocket expenses (travel for treatment, prescriptions, nutritional support)
• Lost income and reduced earning capacity, including lost wages
• Pain and suffering tied to severe pain, vomiting, and ongoing functional limitations
• Costs related to long-term management of digestive injuries and gastroparesis claims (dietary care, specialist treatment)
• Vision-related losses and accommodations for vision loss, if applicable
• Other case-specific losses tied to disability, household assistance, or diminished quality of life

TorHoerman Law investigates Trulicity claims by focusing on medical proof: what you were prescribed, when symptoms started, what your doctors found, and what treatment you required.

We review whether the records support allegations seen in GLP-1 litigation involving severe digestive injuries and vision-related complaints, while accounting for individual risk factors and alternative causes.

Our team gathers the documentation that matters (diagnostic testing, medication history, and specialist evaluations) so your situation can be assessed on its facts, not generalizations about the drug class.

Trulicity is an FDA-cleared diabetes treatment (reflecting FDA approval for its indicated use), but lawsuits examine whether some patients still experienced serious health problems and severe complications that warranted closer scrutiny.

If you believe Trulicity use preceded severe GI symptoms or vision changes, we can review your records and explain what the next steps look like.

Contact TorHoerman Law Today for a free case evaluation.

You can also use the chatbot on this page.